SERVIER
Patient Office

Re: End Brain Cancer Initiative

To Whom It May Concern,

The End Brain Cancer Initiative (EBCI) occupies a unique and vital position in the neuro-oncology space. Their mission—to ensure immediate access to advanced treatments, clinical trials, and top brain tumor specialists—addresses one of the most significant gaps facing patients and families. EBCI's credibility and trust within patient and professional networks enable them to deliver results few organizations can match.

I have worked with Dellann Elliott Mydland and the EBCI team for nearly six years during my time at Servier Pharmaceuticals. They were a highly effective partner and our go-to resource for complex, time-sensitive projects. Involving them early in clinical trial planning and protocol design allowed us to tap into their extensive patient data network for quick-turnaround insights, targeted focus groups, and expert roundtables. These contributions ensured patient voices informed trial protocols, educational materials, and recruitment strategies.

The impact was tangible. Servier credits EBCI and partner organizations for the early accrual of the INDIGO clinical trial, which completed enrollment more than a year ahead of projections. Patient focus groups facilitated by EBCI led to actionable changes in eligibility criteria and development of patient-friendly trial materials.

EBCI's work spans the entire drug lifecycle—from providing patient-centered, operationally feasible study design and input, to recruitment and patient sourcing for even the most complex clinical trials. They deliver high-quality education, identify gaps in access, and engage targeted patient populations, enhancing both company-developed and EBCI-created materials. Their patient engagement facilitation brings together patients, caregivers, and other stakeholders to inform trial planning, execution, and post-approval needs.

A notable example of their impact was during the approval of vorasidenib, where they proactively identified access barriers, advised on solutions, and supported outreach to ensure eligible patients were aware of and connected to treatment opportunities.

Any organization seeking to improve clinical trial engagement, accelerate recruitment, and strengthen patient partnerships will find in EBCI a trusted, high-impact collaborator.

Sincerely,

Wendy L Poage

Wendy Poage
VP, Patient Office
Cell: 617-335-7987